GlobeNewswire Inc | Mar 4, 2021 08:00AM EST

March 04, 2021

WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences.

H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET

Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET

33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Time: 1:30 pm ET

A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimunes website at www.replimune.com. A replay will be available for approximately 90 days following the conference.

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.For more information, please visit www.replimune.com.

Investor Inquiries Chris BrinzeyWestwicke, an ICR Company339.970.2843chris.brinzey@westwicke.com

Media InquiriesArleen Goldenberg Verge Scientific Communications917.548.1582agoldenberg@vergescientific.com